Evaluation of two buflomedil tablet formulations in patients with atherosclerotic disease

M. Molinaro; M. B. Regazzi; S. Raffaghello; I. Buggia; I. Iacona; P. Graziani; G. Specchia; G. M. D'Eril

Evaluation of two buflomedil tablet formulations in patients with atherosclerotic disease

M. Molinaro, M. B. Regazzi, S. Raffaghello, I. Buggia, I. Iacona, P. Graziani, G. Specchia, G. M. D'Eril

IRCCS Fondazione Policlinico San Matteo

Research output: Contribution to journal › Article

Abstract

The bioequivalence of a 600-mg methocel tablet containing buflomedil hydrochloride in sustained-release form was determined relative to a 300-mg CAP/carbovax-coated tablet of buflomedil hydrochloride in immediate-release form. The tablets were given to 20 patients in a double-blind placebo- controlled clinical study with cross-over between the administration plans. The 300-mg tablets were given b.i.d., at 8 a.m. and 8 p.m. while the 600-mg tablets were taken once a day at 8 a.m. (+placebo at 8 p.m.). Plasma samples were collected at appropriate times up to 24 h after administration and were analysed for buflomedil with a validated high-performance liquid chromatographic procedure. Results showed an overall significant mean difference in absorption rate between the two formulations. The mean t(max) (5.5 ± 3.5 h) for the 600-mg tablet was longer (P

Original language	English
Pages (from-to)	111-115
Number of pages	5
Journal	Journal of Clinical Pharmacy and Therapeutics
Volume	19
Issue number	2
Publication status	Published - 1994

Fingerprint

ASJC Scopus subject areas

Pharmacology (medical)
Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Molinaro, M., Regazzi, M. B., Raffaghello, S., Buggia, I., Iacona, I., Graziani, P., Specchia, G., & D'Eril, G. M. (1994). Evaluation of two buflomedil tablet formulations in patients with atherosclerotic disease. Journal of Clinical Pharmacy and Therapeutics, 19(2), 111-115.

@article{4ab82ce317f34147b21f9919711ba45a,

title = "Evaluation of two buflomedil tablet formulations in patients with atherosclerotic disease",

abstract = "The bioequivalence of a 600-mg methocel tablet containing buflomedil hydrochloride in sustained-release form was determined relative to a 300-mg CAP/carbovax-coated tablet of buflomedil hydrochloride in immediate-release form. The tablets were given to 20 patients in a double-blind placebo- controlled clinical study with cross-over between the administration plans. The 300-mg tablets were given b.i.d., at 8 a.m. and 8 p.m. while the 600-mg tablets were taken once a day at 8 a.m. (+placebo at 8 p.m.). Plasma samples were collected at appropriate times up to 24 h after administration and were analysed for buflomedil with a validated high-performance liquid chromatographic procedure. Results showed an overall significant mean difference in absorption rate between the two formulations. The mean t(max) (5.5 ± 3.5 h) for the 600-mg tablet was longer (P",

author = "M. Molinaro and Regazzi, {M. B.} and S. Raffaghello and I. Buggia and I. Iacona and P. Graziani and G. Specchia and D'Eril, {G. M.}",

year = "1994",

language = "English",

volume = "19",

pages = "111--115",

journal = "Journal of Clinical Pharmacy and Therapeutics",

issn = "0269-4727",

publisher = "Wiley-Blackwell",

number = "2",

}

TY - JOUR

T1 - Evaluation of two buflomedil tablet formulations in patients with atherosclerotic disease

AU - Molinaro, M.

AU - Regazzi, M. B.

AU - Raffaghello, S.

AU - Buggia, I.

AU - Iacona, I.

AU - Graziani, P.

AU - Specchia, G.

AU - D'Eril, G. M.

PY - 1994

Y1 - 1994

N2 - The bioequivalence of a 600-mg methocel tablet containing buflomedil hydrochloride in sustained-release form was determined relative to a 300-mg CAP/carbovax-coated tablet of buflomedil hydrochloride in immediate-release form. The tablets were given to 20 patients in a double-blind placebo- controlled clinical study with cross-over between the administration plans. The 300-mg tablets were given b.i.d., at 8 a.m. and 8 p.m. while the 600-mg tablets were taken once a day at 8 a.m. (+placebo at 8 p.m.). Plasma samples were collected at appropriate times up to 24 h after administration and were analysed for buflomedil with a validated high-performance liquid chromatographic procedure. Results showed an overall significant mean difference in absorption rate between the two formulations. The mean t(max) (5.5 ± 3.5 h) for the 600-mg tablet was longer (P

AB - The bioequivalence of a 600-mg methocel tablet containing buflomedil hydrochloride in sustained-release form was determined relative to a 300-mg CAP/carbovax-coated tablet of buflomedil hydrochloride in immediate-release form. The tablets were given to 20 patients in a double-blind placebo- controlled clinical study with cross-over between the administration plans. The 300-mg tablets were given b.i.d., at 8 a.m. and 8 p.m. while the 600-mg tablets were taken once a day at 8 a.m. (+placebo at 8 p.m.). Plasma samples were collected at appropriate times up to 24 h after administration and were analysed for buflomedil with a validated high-performance liquid chromatographic procedure. Results showed an overall significant mean difference in absorption rate between the two formulations. The mean t(max) (5.5 ± 3.5 h) for the 600-mg tablet was longer (P

UR - http://www.scopus.com/inward/record.url?scp=0028283419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028283419&partnerID=8YFLogxK

M3 - Article

C2 - 8071390

AN - SCOPUS:0028283419

VL - 19

SP - 111

EP - 115

JO - Journal of Clinical Pharmacy and Therapeutics

JF - Journal of Clinical Pharmacy and Therapeutics

SN - 0269-4727

IS - 2

ER -

Evaluation of two buflomedil tablet formulations in patients with atherosclerotic disease

Abstract

Fingerprint

ASJC Scopus subject areas

Cite this

Access to Document